{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:32Z","timestamp":1789609112379,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018844","name":"Drs Martin and Dorothy Spatz Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clml.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T16:46:42Z","timestamp":1720975602000},"page":"827-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["On the Way to Curing Advanced-Stage Mycosis Fungoides\/S\u00e9zary Syndrome"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-1934","authenticated-orcid":false,"given":"Seda","family":"Purnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Huen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.07.011_bib0001","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-stage mycosis fungoides and Sezary syndrome: survival and response to treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.07.011_bib0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","article-title":"Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome","volume":"2015","author":"Duvic","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.clml.2024.07.011_bib0003","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"31","key":"10.1016\/j.clml.2024.07.011_bib0004","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.07.011_bib0006","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2024.07.011_bib0007","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2024.07.011_bib0008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich","year":"2009","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2024.07.011_bib0009","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/10428190600709655","article-title":"Sezary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging","volume":"47","author":"Vonderheid","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.clml.2024.07.011_bib0011","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and Sezary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0013","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2024.07.011_bib0014","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"10.1016\/j.clml.2024.07.011_bib0015","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2024.07.011_bib0017","first-page":"825","article-title":"Consensus conference on acute Gvhd grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaad.2011.11.960","article-title":"Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease","volume":"66","author":"Hymes","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ijd.13832","article-title":"The \"Duvic regimen\" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sezary syndrome","volume":"57","author":"Lewis","year":"2018","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0020","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.clml.2024.07.011_bib0021","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clml.2016.08.019","article-title":"Total skin electron beam therapy in the treatment of mycosis fungoides: a review of conventional and low-dose regimens","volume":"16","author":"Chowdhary","year":"2016","journal-title":"Cl Lymph Myelom Leuk"},{"issue":"14","key":"10.1016\/j.clml.2024.07.011_bib0022","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.011_bib0023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1346-8138.16288","article-title":"Pathogenesis of cutaneous T cell lymphoma: involvement of Staphylococcus aureus","volume":"49","author":"Fujii","year":"2022","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2024.07.011_bib0024","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2008.08.030","article-title":"Cutaneous T-cell lymphoma and Staphylococcus aureus colonization","volume":"59","author":"Nguyen","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2014-01-551184","article-title":"Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation","volume":"124","author":"Krejsgaard","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0026","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","article-title":"Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma","volume":"138","author":"Fanok","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"13","key":"10.1016\/j.clml.2024.07.011_bib0027","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.07.011_bib0028","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0029","doi-asserted-by":"crossref","first-page":":41","DOI":"10.1038\/s41409-023-02122-0","article-title":"Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis","volume":"59","author":"Goyal","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.07.011_bib0030","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41409-022-01787-3","article-title":"Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides","volume":"57","author":"Elliott","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.clml.2024.07.011_bib0031","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"issue":"29","key":"10.1016\/j.clml.2024.07.011_bib0032","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.011_bib0033","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2024.07.011_bib0034","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1080\/10428194.2020.1790555","article-title":"Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma delta T cell lymphomas","volume":"61","author":"Isufi","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.07.011_bib0035","article-title":"Skin recurrence of transformed mycosis fungoides postumbilical cord blood transplant despite complete donor chimerism","volume":"2014","author":"Pawar","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.07.011_bib0036","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2024.07.011_bib0037","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0038","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","article-title":"Hematopoietic stem cell transplant for mycosis fungoides and Sezary syndrome","volume":"33","author":"Virmani","year":"2015","journal-title":"Dermatol Clin"},{"issue":"23","key":"10.1016\/j.clml.2024.07.011_bib0039","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","article-title":"Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy","volume":"116","author":"Berger","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal photopheresis in the treatment of mycosis fungoides and Sezary syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0041","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","article-title":"U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease","volume":"158","author":"Scarisbrick","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4 Suppl","key":"10.1016\/j.clml.2024.07.011_bib0042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0043","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0044","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.011_bib0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ijd.13589","article-title":"Occupational mycosis fungoides - a case series","volume":"56","author":"Slodownik","year":"2017","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2024.07.011_bib0046","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0536.1985.tb02532.x","article-title":"Patch tests in Sezary syndrome and mycosis fungoides","volume":"13","author":"Shupp","year":"1985","journal-title":"Contact Dermatitis"},{"issue":"5","key":"10.1016\/j.clml.2024.07.011_bib0047","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0048","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2008-04-153031","article-title":"Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome","volume":"113","author":"van Doorn","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.07.011_bib0049","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.clml.2024.07.011_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0360-3016(97)00553-1","article-title":"Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides)","volume":"40","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"10.1016\/j.clml.2024.07.011_bib0051","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2024.07.011_bib0052","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:47:56Z","timestamp":1732538876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2152265024002684"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the Way to Curing Advanced-Stage Mycosis Fungoides\/S\u00e9zary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}